UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2509-2516

2001

Volltextzugriff (PDF)

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii732-viii732

2018

Volltextzugriff (PDF)

Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3316-3322

1998

Volltextzugriff (PDF)

A Unique Geographical Analysis of Lung Cancer Patients in the State of Utah

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S572-S572

2012

Volltextzugriff (PDF)

Paclitaxel in advanced non-small cell lung cancer: An alternative high-dose weekly schedule

Chest, 2000-04, Vol.117 (4), p.152S-155S

AKERLEY, W. III

2000

Volltextzugriff (PDF)

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity

Annals of oncology, 2004-07, Vol.15 (7), p.1033-1041

2004

Volltextzugriff (PDF)

High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

Journal of clinical oncology, 1998-04, Vol.16 (4), p.1561-1567

1998

Volltextzugriff (PDF)

MA03.10 Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S365-S365

2018

Volltextzugriff (PDF)

1335P Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC

Annals of oncology, 2023-10, Vol.34, p.S770-S770

2023

Volltextzugriff (PDF)

Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure

Cellular and molecular life sciences : CMLS, 2002-07, Vol.59 (7), p.1198-1211

2002

Volltextzugriff (PDF)

P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S369-S370

2019

Volltextzugriff (PDF)

P27.01 Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1040-S1040

2021

Volltextzugriff (PDF)

P63.11 Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1186-S1187

2021

Volltextzugriff (PDF)

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516

2011

Volltextzugriff (PDF)

1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors

Annals of oncology, 2021-09, Vol.32, p.S862-S863

2021

Volltextzugriff (PDF)

Sequential Versus Concurrent Chemoradiotherapy for Post-Operative pN2-N3 Non–Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.S106-S106

2017

Volltextzugriff (PDF)

P01.07 Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S238-S239

2021

Volltextzugriff (PDF)

P89.05 Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S690-S690

2021

Volltextzugriff (PDF)

P15.02 Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S344-S344

2021

Volltextzugriff (PDF)

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer

Journal of clinical oncology, 1994-12, Vol.12 (12), p.2682-2686

1994

Volltextzugriff (PDF)

P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S325

2023

Volltextzugriff (PDF)

1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study

Annals of oncology, 2023-10, Vol.34, p.S810-S810

2023

Volltextzugriff (PDF)

Phase I trial of weekly paclitaxel in advanced lung cancer

Journal of clinical oncology, 1998-01, Vol.16 (1), p.153-158

1998

Volltextzugriff (PDF)

Outcomes Among African-American/Non-African-American Patients With Advanced Non-Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B

JNCI : Journal of the National Cancer Institute, 2002-02, Vol.94 (4), p.284-290

2002

Volltextzugriff (PDF)

FP07.17 The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S211-S211

2021

Volltextzugriff (PDF)

1 – 25 von 177

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(172)
Mit Volltextzugriff
(131)

Publikationsform

Sprache

Englisch
(177)
Japanisch
(7)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(85)
Science & Technology
(71)
Life Sciences & Biomedicine
(68)
Oncology
(51)
Female
(50)
Male
(49)
Middle Aged
(44)
Biological And Medical Sciences
(40)
Medical Sciences
(40)
Aged
(39)
Adult
(34)
Combined Modality Therapy
(27)
Lung Neoplasms - Drug Therapy
(27)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(26)
Paclitaxel - Administration & Dosage
(26)
Pharmacology. Drug Treatments
(25)
Antineoplastic Agents
(24)
Chemotherapy
(22)
Aged, 80 And Over
(20)
Lung Neoplasms - Pathology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

A Unique Geographical Analysis of Lung Cancer Patients in the State of Utah

Paclitaxel in advanced non-small cell lung cancer: An alternative high-dose weekly schedule

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity

High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

MA03.10 Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer

1335P Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC

Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure

P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers

P27.01 Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures

P63.11 Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors

Sequential Versus Concurrent Chemoradiotherapy for Post-Operative pN2-N3 Non–Small Cell Lung Cancer

P01.07 Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6

P89.05 Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis

P15.02 Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer

P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics

1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study

Phase I trial of weekly paclitaxel in advanced lung cancer

Outcomes Among African-American/Non-African-American Patients With Advanced Non-Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B

FP07.17 The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC

Suchergebnisse filtern